JP2023542541A5 - - Google Patents

Info

Publication number
JP2023542541A5
JP2023542541A5 JP2023518858A JP2023518858A JP2023542541A5 JP 2023542541 A5 JP2023542541 A5 JP 2023542541A5 JP 2023518858 A JP2023518858 A JP 2023518858A JP 2023518858 A JP2023518858 A JP 2023518858A JP 2023542541 A5 JP2023542541 A5 JP 2023542541A5
Authority
JP
Japan
Prior art keywords
compound according
heterocyclyl
aryl
cycloalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/052044 external-priority patent/WO2022067094A1/en
Publication of JP2023542541A publication Critical patent/JP2023542541A/ja
Publication of JP2023542541A5 publication Critical patent/JP2023542541A5/ja
Pending legal-status Critical Current

Links

JP2023518858A 2020-09-25 2021-09-24 Mas関連gタンパク質受容体x2のモジュレーター、並びに関連製品及び方法 Pending JP2023542541A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063083638P 2020-09-25 2020-09-25
US63/083,638 2020-09-25
US202163145407P 2021-02-03 2021-02-03
US63/145,407 2021-02-03
US202163211987P 2021-06-17 2021-06-17
US63/211,987 2021-06-17
PCT/US2021/052044 WO2022067094A1 (en) 2020-09-25 2021-09-24 Modulators of mas-related g-protein receptor x2 and related products and methods

Publications (2)

Publication Number Publication Date
JP2023542541A JP2023542541A (ja) 2023-10-10
JP2023542541A5 true JP2023542541A5 (cg-RX-API-DMAC7.html) 2024-10-02

Family

ID=78302949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518858A Pending JP2023542541A (ja) 2020-09-25 2021-09-24 Mas関連gタンパク質受容体x2のモジュレーター、並びに関連製品及び方法

Country Status (11)

Country Link
US (2) US11919864B2 (cg-RX-API-DMAC7.html)
EP (1) EP4217345A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023542541A (cg-RX-API-DMAC7.html)
KR (1) KR20230097015A (cg-RX-API-DMAC7.html)
CN (1) CN116406357A (cg-RX-API-DMAC7.html)
AU (1) AU2021347360A1 (cg-RX-API-DMAC7.html)
CA (1) CA3193207A1 (cg-RX-API-DMAC7.html)
IL (1) IL301575A (cg-RX-API-DMAC7.html)
MX (1) MX2023003476A (cg-RX-API-DMAC7.html)
WO (1) WO2022067094A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202304729B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021347360A1 (en) * 2020-09-25 2023-05-25 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x2 and related products and methods
EP4232042A1 (en) * 2020-10-21 2023-08-30 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x2 and related products and their use
PE20250789A1 (es) 2022-03-30 2025-03-14 Escient Pharmaceuticals Inc Derivados de quinolina como moduladores del receptor x2 de la proteina g relacionados con mas y productos relacionados
CN115850250B (zh) * 2022-10-25 2025-12-23 南京师范大学 一种可控可视化的一氧化碳释放剂及其制备方法和应用
CN121532382A (zh) * 2023-07-13 2026-02-13 北京普祺医药科技股份有限公司 Mas相关g蛋白受体x2的拮抗剂及其用途
US20250084063A1 (en) 2023-08-18 2025-03-13 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
CN119504738A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为mrgprx2拮抗剂的化合物及其制备方法和应用
CN120118069A (zh) * 2023-12-08 2025-06-10 武汉人福创新药物研发中心有限公司 Mrgprx2拮抗剂及用途
WO2025140279A1 (zh) 2023-12-25 2025-07-03 上海森辉医药有限公司 季铵化合物及其药物用途
CN120329282A (zh) * 2024-01-17 2025-07-18 武汉人福创新药物研发中心有限公司 Mas相关g蛋白受体x2拮抗剂及用途
WO2025160430A1 (en) 2024-01-25 2025-07-31 Incyte Corporation Bicyclic heterocycles as mrgprx2 antagonists
WO2025222040A1 (en) 2024-04-19 2025-10-23 Escient Pharmaceuticals, Inc. Mrgprx2 modulators for use in treating mrgprx2 dependent conditions in subjects with low ige
WO2025223036A1 (zh) * 2024-04-23 2025-10-30 凯复(苏州)生物医药有限公司 Mrgprx2拮抗剂、包含其的药物组合物及其用途
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026009854A1 (ja) * 2024-07-01 2026-01-08 日本たばこ産業株式会社 ピリダジノン化合物及びその医薬用途
US12630562B2 (en) 2024-08-07 2026-05-19 Arcus Biosciences, Inc. Piperidylurea compounds and methods of use thereof
WO2026037254A1 (zh) * 2024-08-10 2026-02-19 杭州英创医药科技有限公司 作为mrgprx2拮抗剂的化合物
WO2026064344A1 (en) * 2024-09-17 2026-03-26 Solu Therapeutics, Inc. Heterobifunctional molecules for binding mrgx2 and methods of treating medical conditions using same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030085005A (ko) 2001-03-19 2003-11-01 니뽄 신야쿠 가부시키가이샤 진양제
KR100957516B1 (ko) * 2001-08-15 2010-05-14 이코스 코포레이션 2h-프탈라진-1-온 및 이것의 사용 방법
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
JP2006519258A (ja) * 2003-02-28 2006-08-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ii受容体拮抗薬
US20070185079A1 (en) * 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
JP2006124387A (ja) * 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
CN102625799A (zh) * 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
AU2012335978A1 (en) * 2011-11-08 2014-05-22 Arena Pharmaceuticals, Inc. Modulators of the G protein-coupled Mas receptor and the treatment of disorders related thereto
BR122021012629B1 (pt) * 2013-02-01 2022-06-07 Wellstat Therapeutics Corporation Compostos de amina, composição compreendendo os referidos compostos e usos dos mesmos
AU2021347360A1 (en) * 2020-09-25 2023-05-25 Escient Pharmaceuticals, Inc. Modulators of mas-related g-protein receptor x2 and related products and methods

Similar Documents

Publication Publication Date Title
JP2021523221A5 (cg-RX-API-DMAC7.html)
JP2022522778A5 (cg-RX-API-DMAC7.html)
JP2024524766A5 (cg-RX-API-DMAC7.html)
SI2961736T1 (en) Histone demethylase inhibitors
JP2020536069A5 (cg-RX-API-DMAC7.html)
JP2020521767A5 (cg-RX-API-DMAC7.html)
JP2021534124A5 (cg-RX-API-DMAC7.html)
IL276152B2 (en) Estrogen receptor-modulating compounds
JP2009536620A5 (cg-RX-API-DMAC7.html)
JP2022519239A5 (cg-RX-API-DMAC7.html)
JP2008513498A5 (cg-RX-API-DMAC7.html)
JP2004509952A5 (cg-RX-API-DMAC7.html)
JP2017525757A5 (cg-RX-API-DMAC7.html)
JP2020504707A5 (cg-RX-API-DMAC7.html)
JP2005524609A5 (cg-RX-API-DMAC7.html)
JP2020511536A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)
RU2009146124A (ru) Дигидрохиноновые и дигидронафтиридиновые ингибиторы киназы jnk
RU2010136721A (ru) Агонисты мускариновых рецепторов, композиции, способы лечения ими и способы их изготовления
JP2021504314A5 (cg-RX-API-DMAC7.html)
JP2023513373A5 (cg-RX-API-DMAC7.html)
JP2024523488A5 (cg-RX-API-DMAC7.html)
JP2004525183A5 (cg-RX-API-DMAC7.html)
RU2008107765A (ru) Макроциклические ингибиторы вируса гепатита с
JP2024535128A5 (cg-RX-API-DMAC7.html)